References
Treatment
T1. National Institute for Clinical Evidence. Technology appraisal
No. 32. Guidance on the use of beta interferon and glatiramer acetate for the treatment of multiple
sclerosis. London: National Institute for Clinical Evidence, 2002:
www.nice.org.uk.
T2. Munschauer M and Stuart W. Rationale for early treatment
with interferon beta-1a in relapsing remitting multiple sclerosis. Clinical Therapeutics, 1997, vol
19
.
T3. Teva Pharmaceuticals Ltd. Copaxone. Summary of Prescribing
Characteristics. Available from
www.medicines.org.uk, last modified 7 february 2006,
accessed 10 September 2007.
T4. Biogen Idec Ltd. Tysabri Summary of Product Characteristics
Available from
www.medicines.org.uk, last modified 28
November 2006, accessed 10 September 2007.
T5. National Institute for Clinical Evidence. Technology appraisal
No. 127. Natalizumab for the treatment of adults with highly active relapsing-remitting multiple
sclerosis. London. National Institute for Clinical Evidence, 2007:
www.nice.org.uk
T6. Biogen Idec Limited. AVONEX Summary of Product Characteristics.
Available from
www.medicines.org.uk, last modified 21
February 2007, accessed 10 September 2007.
T7. Guidelines for the use of beta interferons and glatiramer
acetate in multiple sclerosis. Association of British Neurologists, 2001:
www.theabn.org.
T8. National Institute for Clinical Evidence. Multiple sclerosis.
National clinical guideline for diagnosis and management in primary and secondary care. London:
National Institute for Clinical Evidence, 2004:
www.nice.org.uk.
T9. Serono Europe Limited. Rebif. Summary of Product
Characteristics. Available from
www.medicines.org.uk, last modified May 2007, accessed 10
September 2007.
T10. Bayer Schering Pharma AG. Betaferon. Summary of Product
Characteristics. Available from
www.medicines.org.uk, last modified 29 March 2007, accessed
10 September 2007.
T11. Cost effective provision of disease modifying therapies for
people with multiple sclerosis. Department of Health; London; 2002:
www.doh.gov.uk/publications/coinh.html.
T12. Risk sharing scheme: How will it work? What's the latest? MS
Matters. MS Society; London; 2003:
www.mssociety.org.uk
T13. Leary SM, Thompson AJ. Primary progressive multiple
sclerosis: current and future treatment options. CNS Drugs 2005; 19(5): 369-376.
T14. MS Society. MS Essentials 06: Disease modifying drugs.
Available at
www.mssociety.org.uk Accessed on 26 July 2007.
T15. MS Trust.
www.mstrust.org.uk
Tysabri - factsheet Accessed 28 July 2007
T16. Polman CH, O'Connor PW, Havrdova E, et al. A randomized,
placebo-controlled trial of natalizumab for relapsing multiple sclerosis. New England Journal of
Medicine 2006; 354(9): 899-910.
T17. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus
interferon beta-1a for relapsing multiple sclerosis. New England Journal of Medicine 2006; 354(9):
911-923.
T18. Yousry TA, Major EO, Ryschkewitsch C, et al. Evaluation of
patients treated with natalizumab for progressive multifocal leukoencephalopathy. New England
Journal of Medicine 2006; 354(9): 924-933.
T19. BNF 54, Sep 2007.
T20. Johnson KP, Brooks BR, Cohen JA, et al, Copolymer 1 reduces
relapse rate and improves disability in relapsing-remitting multiple sclerosis: results of a phase
III multicenter, double-blind, placebo-controlled trial. Neurology. 2001: 57 (12 supplement 5):
S16-S24.
T21. Munari L, Lovati R, Bolko A. Therapy with glatiramer acetate
for multiple sclerosis (Cochrane review). In: The Cochrane Library, Issue 3, 2007. Wiley,
Chichester, UK.
Frequently Asked Questions
F1. National Institute for Clinical Evidence. Technology appraisal
No. 32. Guidance on the use of beta interferon and glatiramer acetate for the treatment of multiple
sclerosis. London: National Institute for Clinical Evidence, 2002:
www.nice.org.uk.
F2. Boggild M, Ford H. Neurological disorders: multiple sclerosis.
BMJ Publishing Group; London, UK, 2003:
www.clinicalevidence.com.
F3. Biogen Idec Limited. AVONEX. Summary of Product Characteristics.
Available from
www.medicines.org.uk, last modified 21 February 2007,
accessed 10 September 2007.
F4. Guidelines for the use of beta interferons and glatiramer
acetate in multiple sclerosis. Association of British Neurologists, 2001:
www.theabn.org.
F5. Serono Europe Limited. Rebif. Summary of Product
Characteristics. Available from
www.medicines.org.uk, last modified March 2007, accessed 10
September 2007.
MS the Disease
M1. Noseworthy JH, Lucchinetti C, Rodriguez M, Weinshenker BG.
Multiple sclerosis. N Engl J Med. 2000 Sep 28;343(13):938-52.
M2. NICE. Guidance on the use of beta interferon and glatiramer
acetate for the treatment of multiple sclerosis. London: National Institute for Clinical Evidence.
M2002;Technology appraisal No. 32.
M3. Dangond F. Multiple sclerosis. eMedicine. 2006.
www.emedicine.com
M4. Pittock SJ, McClelland RL, Mayr WT, Jorgensen NW, Weinshenker
BG, Noseworthy J, et al. Clinical implications of benign multiple sclerosis: a 20-year
population-based follow-up study. Ann Neurol. 2004 Aug;56(2):303-6.
M5. Bruck W. The pathology of multiple sclerosis is the result of
focal inflammatory demyelination with axonal damage. J Neurol. 2005 Nov;252 Suppl 5:v3-9.
M6. Dyment DA, Sadovnick AD, Ebers GC. Genetics of multiple
sclerosis. Hum Mol Genet. 1997;6(10):1693-8.
hmg.oxfordjournals.org
M7. Hafler DA, Compston A, Sawcer S, Lander ES, Daly MJ, De Jager
PL, et al. Risk alleles for multiple sclerosis identified by a genomewide study. N Engl J Med. 2007
Aug 30;357(9):851-62.
M8. Van der Mei IA, Ponsonby AL, Dwyer T, Blizzard L, Simmons R,
Taylor BV, et al. Past exposure to sun, skin phenotype, and risk of multiple sclerosis:
case-control study. Bmj. 2003 Aug 9;327(7410):316.
M9. Munger KL, Levin LI, Hollis BW, Howard NS, Ascherio A. Serum
25-hydroxyvitamin D levels and risk of multiple sclerosis. Jama. 2006 Dec 20;296(23):2832-8.
M10. Levin LI, Munger KL, Rubertone MV, Peck CA, Lennette ET,
Spiegelman D, et al. Temporal relationship between elevation of epstein-barr virus antibody titers
and initial onset of neurological symptoms in multiple sclerosis. Jama. 2005 May
25;293(20):2496-500.
M11. Yao SY, Stratton CW, Mitchell WM, Sriram S. CSF oligoclonal
bands in MS include antibodies against Chlamydophila antigens. Neurology. 2001 May 8;56(9):1168-76.
M12. Li J, Johansen C, Bronnum-Hansen H, Stenager E,
Koch-Henriksen N, Olsen J. The risk of multiple sclerosis in bereaved parents: A nationwide cohort
study in Denmark. Neurology. 2004 Mar 9;62(5):726-9.
M13. Franklin GM, Nelson L. Environmental risk factors in multiple
sclerosis: causes, triggers, and patient autonomy. Neurology. 2003 Oct 28;61(8):1032-4.
M14. Multiple Sclerosis Society of America. Symptom management.
2007.
www.msassociation.org
M15. Lublin FD, Reingold SC. Defining the clinical course of
multiple sclerosis: results of an international survey. National Multiple Sclerosis Society (USA)
Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Neurology. 1996
Apr;46(4):907-11.
M16. McDonald WI, Compston A, Edan G, Goodkin D, Hartung HP,
Lublin FD, et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the
International Panel on the diagnosis of multiple sclerosis. Ann Neurol. 2001 Jul;50(1):121-7.
M17. Minneboo A, Barkhof F, Polman CH, Uitdehaag BM, Knol DL,
Castelijns JA. Infratentorial lesions predict long-term disability in patients with initial
findings suggestive of multiple sclerosis. Arch Neurol. 2004 Feb;61(2):217-21.
M18. Tintore M, Rovira A, Rio J, Nos C, Grive E, Tellez N, et al.
Baseline MRI predicts future attacks and disability in clinically isolated syndromes. Neurology.
2006 Sep 26;67(6):968-72.
M19. Jacobs LD, Beck RW, Simon JH, Kinkel RP, Brownscheidle CM,
Murray TJ, et al. Intramuscular interferon beta-1a therapy initiated during a first demyelinating
event in multiple sclerosis. CHAMPS Study Group. N Engl J Med. 2000 Sep 28;343(13):898-904.
M20. Comi G, Filippi M, Barkhof F, Durelli L, Edan G, Fernandez O,
et al. Effect of early interferon treatment on conversion to definite multiple sclerosis: a
randomised study. Lancet. 2001 May 19;357(9268):1576-82.
M21. Kappos L, Freedman MS, Polman CH, Edan G, Hartung HP, Miller
DH, et al. Effect of early versus delayed interferon beta-1b treatment on disability after a first
clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study.
Lancet. 2007 Aug 4;370(9585):389-97.
M22. NICE. Multiple sclerosis. National clinical guideline for
diagnosis and management in primary and secondary care. London: National Institute for Clinical
Evidence. 2004.
www.nice.org.uk
M23. Neurologists AoB. Guidelines on the use of beta interferons
and glatiramer acetate in multiple sclerosis. 2001.
www.theabn.org
M24. National MS Society. The History of MS: The Basic Facts.
National Multiple Sclerosis Society. 2003.
www.nationalmssociety.org
Living with MS
L1. John Campbell. My name is John Campbell and I have MS.
www.msactivesource.com, accessed 28
August 2003.
L2. Penny Camfield. Deep down in Denial.
www.msactivesource.com, accessed 28
August 2003.
L3. Multiple Sclerosis International Federation. Symptoms and
treatments: Relationships, intimacy and sexuality.
www.msif.org,
accessed 14 September 2005.
L4. Multiple sclerosis International Federation. Symptoms and
treatments: sexual dysfunction.
www.msif.org, accessed 14
September 2005.
L5. Greg Dunn.
www.msactivesource.com, accessed 28
August 2003.
L6. Multiple Sclerosis International Federation. Symptoms and
treatments: Lifestyle issues - coping with role changes and loss of intimacy.
www.msif.org, accessed 14 September 2005.
L7. Carers Speak Out Project Report on findings and recommendations.
The Princess Carers Trust.
www.carers.org.uk accessed on 20 October 2007.
L8 .MS Society. Should I tell my employer I have MS?
http://www.mssociety.org.uk/about_ms/employment/telling_your_emp.html
Access on June 8, 2007
L9. Risk sharing scheme: How will it work? What's the latest? MS
Matters. MS Society; London; 2003:
www.mssociety.org.uk
Newly Diagnosed
ND1. What is MS?
MS Active Source leaflet
ND2. Confavreux C, Vukusic S, Moreau T et al. Relapses and
progression of disability in multiple sclerosis. New Eng J Med 2000; 343: 1430-1438.
ND3. MS Society website. What is MS? Availible at
http://www.mssociety.org.uk/about_ms/what_is_ms/index.html
Accessed on 19 June 2007
ND4. National Institute for Health and Clinical Evidence. Clinical
Guideline 8: Multiple sclerosis: Full guideline. Available at
www.nice.org.uk Accessed on June8, 2007.
ND5.
So you have multiple sclerosis... What's next?
Accelerated Cure Project page 5
ND6. Best Treatments. How common is multiple sclerosis?
Available at
http://www.besttreatments.co.uk/btuk/conditions/16743.html Accessed on 19 June 2007
ND7. Thinking about memory and problem solving. Biogen Idec
leaflet
ND8. Specialist Nursing in MS - the way forward: the key elements
for developing MS specialist services in the UK. Leadlet by the MS Trust
ND9. National Institute for Clinical Evidence. Multiple sclerosis.
National clinical guideline for diagnosis and management in primary and secondary care. London:
National Institute for Clinical Evidence, 2004:
www.nice.org.uk
ND10.National Institute for Health and Clinical Evidence. Public
Guidelines. Available at
www.nice.org.uk
ND11.Thinking about telling Family and Friends. Biogen Idec
leaflet.
ND12.MS Society. Should I tell my employer I have MS?
http://www.mssociety.org.uk/about_ms/employment/telling_your_emp.html
Access on June 8, 2007
ND13.Before MS, after MS. Sande Hickey from
MSActiveSource.com.
Accessed on 20 October, 2007.
ND14.Carers Speak Out Project Report on findings and
recommendations. The Princess Carers Trust.
www.carers.org.uk accessed on 20 October 2007.
ND15.Health professionals involved in MS article from MS Trust
www.mstrust.org.uk
accessed on 26 October 2007.
ND16.MS Essentials Women’s issues – pregnancy, menstruation,
contraception and menopause.
www.mssociety.org.uk
accessed on 26 October 2007.